Ajooni Biotech Ltd

Ajooni Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Jan 2026. While the rating was revised at the start of the year, the analysis below reflects the stock's current fundamentals, returns, and financial metrics as of 21 April 2026, providing investors with an up-to-date perspective on the company’s position in the Pharmaceuticals & Biotechnology sector.

Ajooni Biotech Ltd is rated 'Sell' by MarketsMOJO, a rating that was last updated on 01 Jan 2026. While this rating change occurred earlier this year, the analysis and financial metrics discussed here reflect the company’s current position as of 10 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Ajooni Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Ajooni Biotech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 01 Jan 2026. While the rating change occurred at the start of the year, the analysis and financial metrics discussed here reflect the company’s current position as of 16 March 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Ajooni Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with an up-to-date view of the company's standing in the Pharmaceuticals & Biotechnology sector.

Ajooni Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 February 2026, providing investors with the latest insights into its performance and outlook.

Ajooni Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 January 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 February 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Ajooni Biotech Ltd surged to its upper circuit limit on 1 Feb 2026, registering a maximum daily gain of 9.25% amid robust buying interest and heightened investor participation. The stock’s sharp rally outpaced its sector and benchmark indices, reflecting renewed optimism despite its current sell rating and micro-cap status.

Ajooni Biotech Ltd has demonstrated a marked improvement in its financial performance for the quarter ended December 2025, registering its highest quarterly revenue and profitability metrics in recent history. Despite this operational upswing, the company’s stock continues to face headwinds in the broader market, reflecting a complex interplay between fundamental progress and investor sentiment.

Ajooni Biotech Ltd., a micro-cap pharmaceutical company, reported a striking 85.10% quarter-on-quarter revenue surge in Q3 FY26, with net sales reaching ₹58.75 crores compared to ₹31.74 crores in the previous quarter. Net profit for the quarter stood at ₹1.65 crores, marking a 77.42% sequential increase from ₹0.93 crores in Q2 FY26. However, the stock has remained under severe pressure, declining 46.65% over the past year and trading at ₹3.90 against a market capitalisation of ₹67.18 crores, reflecting persistent investor concerns about the company's profitability trajectory and operational efficiency.

Ajooni Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Jan 2026. While the rating was revised at the start of the year, the analysis below reflects the stock’s current fundamentals, returns, and financial metrics as of 30 January 2026, providing investors with an up-to-date view of the company’s position.

Ajooni Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Jan 2026. While the rating was revised at the start of the year, the analysis and financial metrics presented here reflect the stock's current position as of 19 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Ajooni Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Ajooni Biotech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into its performance and outlook.

Ajooni Biotech, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters. This adjustment highlights evolving perspectives on the company’s quality, valuation, financial trajectory, and technical outlook amid a backdrop of sustained stock price declines.